serena williams glp-1 medication What Williams' Story Reveals About Health and Weight Serena Williams lost 14 kg

Novo Nordisk reported $31.1 billion in revenue in 2024 from Ozempic, and Rybelsus , up from $11.9 billion in 2022

So while there are these guidelines, your symptoms and your experience should really guide that

Its true that the FDA has reported adverse events linked to poorly compounded GLP-1s, and professional societies such as the American Diabetes Association have echoed concerns

Future large long-term RCTs with primary or secondary outcomes, including thyroid disorders and real-world data, are needed to elucidate the association between GLP-1 receptor agonists and the risk of various thyroid disorders, particularly thyroid cancer

Peptide Science: Chemical Ligation, Lead Generation, and Therapeutic Advances, 2025: pp

Nov 2023 - The FDA's approval of Eli Lillys Zepbound (tirzepatide) represents a significant advancement in obesity treatment, as it uniquely targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors